FDG-PET for hepatobiliary and pancreatic cancer: Advances and current limitations

doi:10.5306/wjco.v2.i5.229

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 2, Issue 5

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4940)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-11) series.

Item

Count

PDF

405

HTML

4194

Figures (1-11)

341

Sum=4940

May 10, 2011 (publication date) through Nov 22, 2024

Times Cited of This Article

Times Cited (25)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Topic Highlight

World J Clin Oncol. May 10, 2011; 2(5): 229-236
Published online May 10, 2011. doi: 10.5306/wjco.v2.i5.229

Full Size Figure Download Figure

Figure 10 IgG4 related pancreatitis. A: PET/CT shows strong fluorodeoxyglucose (FDG) accumulation in the whole pancreas with swelling (arrow); B: MIP image of PET. Besides diffuse uptake in the pancreas, symmetrical FDG deposits were noted in the bilateral salivary glands and hilar, mediastinal lymph nodes (arrows). Distribution in the involved organs is characteristic of this disease.

Citation: Murakami K. FDG-PET for hepatobiliary and pancreatic cancer: Advances and current limitations. World J Clin Oncol 2011; 2(5): 229-236
URL: https://www.wjgnet.com/2218-4333/full/v2/i5/229.htm
DOI: https://dx.doi.org/10.5306/wjco.v2.i5.229